BRIM Biotechnology, Inc. (TPE:6885)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
22.95
-0.15 (-0.65%)
At close: Apr 28, 2026
-1.50%
Market Cap 3.06B
Revenue (ttm) 5.49M
Net Income (ttm) -436.45M
Shares Out 133.21M
EPS (ttm) -3.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 217,125
Average Volume 290,591
Open 23.20
Previous Close 23.10
Day's Range 22.75 - 23.40
52-Week Range 21.60 - 41.30
Beta 1.05
RSI 37.04
Earnings Date May 8, 2026

About BRIM Biotechnology

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company’s lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that ha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6885
Full Company Profile

Financial Performance

In 2025, BRIM Biotechnology's revenue was 5.49 million, an increase of 1548.65% compared to the previous year's 333,000. Losses were -436.45 million, 38.3% more than in 2024.

Financial Statements

News

There is no news available yet.